Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Lymphoma

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Br J Haematol

Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S, ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.70631

Lymphoma

Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group

Lancet Haematol

Bazarbachi A, Fekom M, Martinez C, Khvedelidze I, Moukalled N, Peggs KS, Halahleh K, Bramanti S, Giebel S, Aljurf M, Sakellari I, Benakli M, Bonifazi F, Cerretti R, Devillier R, Kulagin A, Nicholson E, Forcade E, Walewski J, Tanase A, Sureda A

doi: 10.1016/S2352-3026(26)00169-9

Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Blood

Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I

doi: 10.1182/blood.2025031733

Multiple Myeloma (MM)

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Leuk Lymphoma

Leitner T, Oelschläger L, Henriquez Mosquera F, Schaefers C, Leypoldt L, Weisel K, von Bubnoff N, Rückert M, Kimmich C, Ahmed H, Vorwerk J, Khandanpour C

doi: 10.1080/10428194.2026.2699285

Lymphoma

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Haematologica

Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Labouré G, Laribi K, Gros FX, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J

doi: 10.3324/haematol.2025.300289

Lymphoma

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Blood Cancer J

Perrone S, Molica M, Giannarelli D, Pacitto G, Ferrero S

doi: 10.1038/s41408-026-01552-5

Multiple Myeloma (MM)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Am J Hematol

Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Martínez-Lopez J, Kastritis E, Chng WJ, Kapoor P, Dave M, Bal S, Garderet L, Corraes AMS, Riedhammer C, Steinbrunn T, Corona M, Nagarajan C, Einsele H, Martin T, Krishnan A, Lin Y

doi: 10.1002/ajh.70376

Lymphoma

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

Am J Hematol

Gugliotta G, Argnani L, Cantelli M, Pinto A, Gorgone A, Piazza F, Fozza C, Fesce VF, Marino F, Celli M, Pennese E, Gaudio F, Lauzzana P, Pezzullo L, Lorenzo S, Nierychlewska PM, Ceparano G, Pane F, Casadei B, Pellegrini C, Romano C, Zinzani PL

doi: 10.1002/ajh.70317

Related content

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma